{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:31:59Z","timestamp":1789612319523,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"La Ligue Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009468","name":"R\u00e9gion Nouvelle-Aquitaine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbcan.2026.189620","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:03:38Z","timestamp":1779980618000},"page":"189620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies"],"prefix":"10.1016","volume":"1881","author":[{"given":"Geraldine","family":"Siegfried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Badiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.M.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Majid","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189620_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112923","article-title":"Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: strategies and perspectives","volume":"149","author":"Cui","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189620_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-021-00569-4","article-title":"Optimizing immunotherapy for colorectal cancer","volume":"19","author":"Ganesh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer","volume":"13","author":"Ros","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0020","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41577-023-00890-w","article-title":"Regulatory T cells in the face of the intestinal microbiota","volume":"23","author":"Ramanan","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1665488","article-title":"Recent advances in adoptive cell therapy for cancer immunotherapy","volume":"16","author":"Qian","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189620_bb0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI74894","article-title":"Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis","volume":"125","author":"Reissfelder","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189620_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189620_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104135","article-title":"Immunotherapy-related biomarkers: confirmations and uncertainties","volume":"192","author":"Catalano","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of Pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0075","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12672-024-01117-7","article-title":"The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer","volume":"15","author":"Chuang","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1016646","article-title":"Mechanism and strategies of immunotherapy resistance in colorectal cancer","volume":"13","author":"Shan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0095","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers15102858","article-title":"Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24141","article-title":"Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer","volume":"36","author":"Du","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bbcan.2026.189620_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189620_bb0110","article-title":"Mutant KRAS drives immune evasion by sensitizing cytotoxic T-cells to activation-induced cell death in colorectal Cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0115","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/ijms25063304","article-title":"Targeting KRAS G12C mutation in colorectal cancer, a review: new arrows in the quiver","volume":"25","author":"Ros","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0120","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-19-0086","article-title":"Inactivation of Proprotein convertases in T cells inhibits PD-1 expression and creates a favorable immune microenvironment in colorectal Cancer","volume":"79","author":"Tom\u00e9","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011364","article-title":"Blockade of colon cancer metastasis via single and double silencing of PCSK7\/PCSK9: Enhanced T cells cytotoxicity in mouse and human","volume":"13","author":"Porcheron","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0130","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41388-021-02175-9","article-title":"The proprotein convertase furin in cancer: more than an oncogene","volume":"41","author":"He","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189620_bb0135","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Ng","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41416-022-02073-1","article-title":"Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer","volume":"128","author":"Fran\u00e7ois","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2019.12.027","article-title":"Proprotein convertases: key players in inflammation-related malignancies and metastasis","volume":"473","author":"Siegfried","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189620_bb0150","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ijc.30714","article-title":"The proprotein convertase furin in tumour progression","volume":"141","author":"Jaaks","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2017.04.027","article-title":"Proprotein convertase inhibition: paralyzing the cell's master switches","volume":"140","author":"Klein-Szanto","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189620_bb0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1152\/physrev.00008.2021","article-title":"Altered islet prohormone processing: a cause or consequence of diabetes?","volume":"102","author":"Ramzy","year":"2022","journal-title":"Physiol. Rev."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189620_bb0170","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.2741\/3055","article-title":"Knock-out mouse models of proprotein convertases: unique functions or redundancy?","author":"Creemers","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0175","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1073\/pnas.89.18.8822","article-title":"Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3","volume":"89","author":"Smeekens","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189620_bb0180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0185","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab155","article-title":"Obesity, POMC, and POMC-processing enzymes: surprising results from animal models","volume":"162","author":"Lindberg","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbcan.2026.189620_bb0190","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1152\/physrev.00057.2024","article-title":"Proglucagon-derived peptides: human physiology and therapeutic potential","volume":"106","author":"Gasbjerg","year":"2026","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbcan.2026.189620_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/humupd\/dmn060","article-title":"Proprotein convertase subtilisin\/kexin type 4 in mammalian fertility: a review","volume":"15","author":"Gyamera-Acheampong","year":"2009","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.bbcan.2026.189620_bb0200","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10142-025-01694-y","article-title":"MBTPS1: a membrane-bound transcription factor protease implicated in the pathogenesis of several skin and skeletal disorders","volume":"25","author":"Huang","year":"2025","journal-title":"Funct. Integr. Genomics"},{"key":"10.1016\/j.bbcan.2026.189620_bb0205","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MOL.0000000000001003","article-title":"SPRINGing off the lock: the role of SPRING in S1P activity and SREBP-regulated lipid metabolism","volume":"36","author":"Micallo","year":"2025","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0210","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbcan.2026.189620_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667850","article-title":"The role of Proprotein convertases in the regulation of the function of immune cells in the Oncoimmune response","volume":"12","author":"Rose","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nature07210","article-title":"T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance","volume":"455","author":"Pesu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189620_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250246","article-title":"FURIN regulates cytotoxic T-lymphocyte effector function and memory cell transition in mice","volume":"53","author":"Ojanen","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/srep19360","article-title":"The proprotein convertase PC1\/3 regulates TLR9 trafficking and the associated signaling pathways","volume":"6","author":"Duhamel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0235","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein. Cell."},{"key":"10.1016\/j.bbcan.2026.189620_bb0240","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1074\/jbc.M807322200","article-title":"Foxp3 processing by proprotein convertases and control of regulatory T cell function","volume":"284","author":"de Zoeten","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189620_bb0245","doi-asserted-by":"crossref","first-page":"54392","DOI":"10.18632\/oncotarget.11106","article-title":"Myeloid cell expressed proprotein convertase FURIN attenuates inflammation","volume":"7","author":"Cordova","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189620_bb0250","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41419-024-07267-4","article-title":"Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities","volume":"15","author":"Ziane-Chaouche","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189620_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121490","article-title":"PC1\/3 KD macrophages exhibit resistance to the inhibitory effect of IL-10 and a higher TLR4 activation rate, leading to an anti-tumoral phenotype","volume":"8","author":"Rodet","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189620_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107490","article-title":"PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis","volume":"159","author":"Suur","year":"2025","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0265","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0270","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.chom.2011.02.006","article-title":"Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell specific manner","volume":"9","author":"Popkin","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbcan.2026.189620_bb0275","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1038\/s41467-025-59193-4","article-title":"Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189620_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12758","article-title":"PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque","author":"Liu","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbcan.2026.189620_bb0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-61779-204-5_3","article-title":"The proprotein convertases, 20 years later","volume":"768","author":"Seidah","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0290","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.R113.481549","article-title":"The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions","volume":"288","author":"Seidah","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189620_bb0295","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.immuni.2013.09.004","article-title":"Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes","volume":"39","author":"Hipp","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189620_bb0300","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.1516000113","article-title":"Autoinhibition and relief mechanism by the proteolytic processing of toll-like receptor 8","volume":"113","author":"Tanji","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189620_bb0305","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189620_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065600","article-title":"Interplay between signaling pathways and tumor microenvironment components: a paradoxical role in colorectal cancer","volume":"24","author":"Ben Hamouda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/cac2.12295","article-title":"Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy","volume":"42","author":"Bhat","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0320","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cells12081139","article-title":"TGF\u03b2 and the tumor microenvironment in colorectal cancer","volume":"12","author":"Waldner","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189620_bb0325","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/cells11030398","article-title":"KRAS as a modulator of the inflammatory tumor microenvironment: therapeutic implications","volume":"11","author":"Pereira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189620_bb0330","article-title":"Mutant KRAS drives immune evasion by sensitizing cytotoxic T-Cells to activation-induced cell death in colorectal cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0335","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jtho.2019.02.004","article-title":"The combination of MEK inhibitor with immunomodulatory antibodies targeting PD-1 and PD-L1 results in prolonged survival in Kras\/p53-driven lung Cancer","volume":"14","author":"Lee","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/mmr.2024.13389","article-title":"KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF-\u03b2 mediated epithelial-mesenchymal transition","volume":"31","author":"Guo","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0345","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.5280","article-title":"MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells","volume":"249","author":"Stutvoet","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0350","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0355","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-20-1112","article-title":"ERK inhibition improves anti-PD-L1 immune checkpoint blockade in preclinical pancreatic ductal adenocarcinoma","volume":"20","author":"Henry","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189620_bb0360","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0365","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/1878-0261.13163","article-title":"KRAS mutation-independent downregulation of MAPK\/PI3K signaling in colorectal cancer","volume":"16","author":"Lam","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0375","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","article-title":"MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors","volume":"72","author":"Turke","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0380","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-15-1377","article-title":"Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS-mutant lung Cancer","volume":"6","author":"Kitai","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0385","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0390","doi-asserted-by":"crossref","first-page":"14472","DOI":"10.18632\/oncotarget.3991","article-title":"Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189620_bb0395","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41419-022-04941-3","article-title":"Blocking STAT3 signaling augments MEK\/ERK inhibitor efficacy in esophageal squamous cell carcinoma","volume":"13","author":"Zheng","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189620_bb0400","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0405","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","article-title":"Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal Cancer","volume":"13","author":"Yaeger","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189620_bb0410","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189620_bb0415","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-024-00793-6","article-title":"Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization","volume":"9","author":"Maruyama","year":"2025","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0420","series-title":"WNT signalling promotes NF-\u03baB activation and drug resistance in KRAS-mutant colorectal cancer | EMBO reports","year":"2026"},{"key":"10.1016\/j.bbcan.2026.189620_bb0425","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neo.2016.09.004","article-title":"Metabolic alterations caused by KRAS mutations in colorectal cancer contribute to cell adaptation to glutamine depletion by upregulation of asparagine synthetase","volume":"18","author":"Toda","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189620_bb0430","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/cancers14051195","article-title":"Role of Furin in Colon Cancer stem cells malignant phenotype and expression of LGR5 and NANOG in KRAS and BRAF-mutated Colon tumors","volume":"14","author":"Descarpentrie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0435","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/s41388-020-1238-z","article-title":"The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer","volume":"39","author":"He","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189620_bb0440","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1038\/s41598-022-11697-5","article-title":"Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells","volume":"12","author":"Saliani","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0445","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.cell.2016.11.035","article-title":"Mutant KRAS enhances tumor cell fitness by upregulating stress granules","volume":"167","author":"Grabocka","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189620_bb0450","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.3390\/cancers3043894","article-title":"The crosstalk of PTGS2 and EGF signaling pathways in colorectal Cancer","volume":"3","author":"Wang","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0455","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1055-9965.EPI-13-0263","article-title":"PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review","volume":"22","author":"Kunzmann","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.bbcan.2026.189620_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158094","article-title":"Association of KRAS mutation and gene pathways in colorectal carcinoma: a transcriptome- and methylome-wide study and potential implications for therapy","volume":"25","author":"Jasmine","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0465","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2020.08.019","article-title":"Nuclear protein 1 imparts oncogenic potential and chemotherapeutic resistance in Cancer","volume":"494","author":"Murphy","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189620_bb0470","doi-asserted-by":"crossref","first-page":"16999","DOI":"10.1038\/s41598-018-35020-3","article-title":"Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis","volume":"8","author":"Santofimia-Casta\u00f1o","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0475","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/sj.onc.1210914","article-title":"TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition","volume":"27","author":"Jung","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189620_bb0480","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/0008-5472.CAN-16-1267-T","article-title":"PROTOCADHERIN 7 acts through SET and PP2A to potentiate MAPK signaling by EGFR and KRAS during lung tumorigenesis","volume":"77","author":"Zhou","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0485","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6604664","article-title":"CD133 expression is an independent prognostic marker for low survival in colorectal cancer","volume":"99","author":"Horst","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189620_bb0490","first-page":"85","article-title":"The role of Lama2 in Cancer: current perspectives","volume":"10","author":"Hu","year":"2022","journal-title":"Cancer Res. J."},{"key":"10.1016\/j.bbcan.2026.189620_bb0495","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4602570","article-title":"Integrin \u03b19 suppresses hepatocellular carcinoma metastasis by rho GTPase signaling","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0500","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/emboj.2012.150","article-title":"The many faces and functions of \u03b2-catenin","volume":"31","author":"Valenta","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2026.189620_bb0505","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1093\/nar\/gkr1139","article-title":"Structure of Musashi1 in a complex with target RNA: the role of aromatic stacking interactions","volume":"40","author":"Ohyama","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189620_bb0510","article-title":"The role of CAF-derived Vitronectin in promoting colorectal Cancer progression and immunosuppression","volume":"12","author":"Yu","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189620_bb0515","doi-asserted-by":"crossref","first-page":"16330","DOI":"10.1038\/s41598-020-73500-7","article-title":"Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189620_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf5473","article-title":"CECR2 drives breast cancer metastasis by promoting NF-\u03baB signaling and macrophage-mediated immune suppression","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189620_bb0525","doi-asserted-by":"crossref","first-page":"102783","DOI":"10.18632\/oncotarget.22245","article-title":"Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity","volume":"8","author":"Kaller","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189620_bb0530","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.3390\/ijms25179199","article-title":"Development and prospects of Furin inhibitors for therapeutic applications","volume":"25","author":"Ivachtchenko","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189620_bb0535","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.95.13.7293","article-title":"alpha1-antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent","volume":"95","author":"Jean","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189620_bb0540","doi-asserted-by":"crossref","first-page":"10326","DOI":"10.1073\/pnas.191199198","article-title":"Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells","volume":"98","author":"Bassi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189620_bb0545","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1172\/JCI32040","article-title":"Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells","volume":"118","author":"Scamuffa","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189620_bb0550","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1593\/neo.08166","article-title":"A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness","volume":"10","author":"Coppola","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189620_bb0555","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/cmdc.201500103","article-title":"Novel Furin inhibitors with potent anti-infectious activity","volume":"10","author":"Hardes","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbcan.2026.189620_bb0560","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.chembiol.2022.02.001","article-title":"A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease","volume":"29","author":"Douglas","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0565","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1021\/jm3011178","article-title":"The multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells","volume":"55","author":"Levesque","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189620_bb0570","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.18632\/oncotarget.2918","article-title":"PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation","volume":"6","author":"Levesque","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189620_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189620_bb0580","doi-asserted-by":"crossref","first-page":"62","DOI":"10.33696\/cancerimmunol.6.086","article-title":"Combining EGFR and KRAS G12C inhibitors for KRAS G12C mutated advanced colorectal cancer","volume":"6","author":"Miyashita","year":"2024","journal-title":"J. Cancer Immunol. (Wilmington)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:26:30Z","timestamp":1785072390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0304419X26000922"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189620","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189620"}}